LOY-002, Loyal’s Senior Dog Longevity Drug, Reaches Important FDA Milestone
Last updated on March 9th, 2025 at 12:58 pm
Good news to all senior dog owners!
LOY-002, a new drug being developed by Loyal, has earned its formal FDA acceptance for reasonable expectation of efficacy (RXE).
This means that the LOY-002 is one step closer to becoming the world’s first FDA-approved longevity drug for senior dogs.
What Is LOY-002?
LOY-002 is a daily pill designed for senior dogs aged 10 years and older, who weigh at least 14 pounds.
As dogs age, their metabolism slows down, which can lead to age-related diseases and a shorter, less active life.
LOY-002 works by helping to support a healthier metabolism, aiming to slow down the aging process and help dogs live longer healthier lives.
The goal of LOY-002 is to give dog owners more happy years with their dogs, more energy, more playtime, and a better quality of life in their senior years.
About Loyal
Loyal is a veterinary medicine company focused on helping dogs live longer, healthier lives.
Since its founding in 2019, Loyal has been working to develop safe and effective longevity drugs designed specifically for dogs — all backed by scientific research and rigorous testing.
With over $150 million in funding and a team of scientists, veterinarians, and longevity experts, Loyal is committed to bringing the first FDA-approved longevity drugs for dogs to market.
Every step of the process — from research to clinical trials — is done with one goal in mind: to give dogs more healthy years with the people who love them.
Loyal’s Other Longevity Drugs For Senior Dogs
In addition to LOY-002, Loyal is also developing two other products aimed at helping large and giant breed dogs live longer, healthier lives:
LOY-001
An injectable drug administered by a veterinarian a few times a year. This long-acting treatment is designed for large and giant breed dogs, who tend to age faster than smaller dogs.
LOY-003
A daily pill prescribed by a veterinarian. Like LOY-001, this product focuses on supporting healthy aging and extending lifespan, but in a convenient daily tablet form.
Both LOY-001 and LOY-003 are currently in the pilot study stage, with Loyal targeting FDA approval by 2027.
Together with LOY-002, these products are part of Loyal’s mission to develop science-backed medicines that give dogs of all sizes more healthy years with their families.
To learn more about both products, visit: https://loyal.com/products
Continued Progress and New Funding Milestone
According to Celine Halioua, Founder & CEO of Loyal, the FDA milestone for LOY-002 is just one part of the company’s recent progress.
While advancing its longevity programs, Loyal also raised an additional $22 million as part of a Series B-2 funding round, bringing the company’s total funding to over $150 million since its founding in 2019.
These two achievements — regulatory progress and strong financial backing — demonstrate Loyal’s continued momentum toward delivering the world’s first FDA-approved longevity drug for dogs.
With this combination of scientific progress and investor confidence, Loyal is well-positioned to continue developing safe, effective longevity treatments to help dogs live longer, healthier lives.
Stay Connected With Loyal
To keep up with Loyal’s latest updates, including news on LOY-001, LOY-002, and LOY-003, follow them on Facebook, Instagram, and LinkedIn or subscribe to their email list.
